Neogenomics Inc (NASDAQ:NEO)
| 8.82 Delayed Data As of Jul 06 |  -0.43 / -4.65%Today’s Change | 6.85 Today|||52-Week Range 54.74 | -74.15% Year-to-Date |
| SECTOR Health Services | INDUSTRY Medical/Nursing Services | MARKET CAP $1.0B |
Company Description
NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials and research. It also provides testing services in support of its pharmaceutical clients' oncology programs from discovery to commercialization. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.
Contact Information
NeoGenomics, Inc. 9490 NeoGenomics Way Fort Myers Florida 33912 |
Employees
Shareholders
| Mutual fund holders | 57.01% |
| Other institutional | 32.87% |
| Individual stakeholders | 10.50% |
Top Executives
| Lynn A. Tetrault | Chairman & Chief Executive Officer |
| Bill Bonello | Chief Financial Officer |
| Steven A. Ross | Chief Information Officer & Vice President |
| David Sholehvar | President-Clinical Services |
| John Mooney | Chief Technology Officer |
